Thus, to address these contradictory findings arising from the pharmacological evidence, we generated a line of transgenic (Tg) AD mice expressing a genetically induced deficit in amylin/calcitonin receptors, but carrying the full amyloid protein precursor (APP) gene and resultant overexpression of Aβ. This evidence concerns the gene APP and Alzheimer disease.